Post-operative stimulated thyroglobulin and neck ultrasound as personalized criteria for risk stratification and radioactive iodine selection in low- and intermediate-risk papillary thyroid cancer.

Endocrine

Endocrine Division, Department of Medicine, Joseph and Mildred Sonshine Family Centre for Head & Neck Diseases, Mount Sinai Hospital, 413-7, 600 University Avenue, Toronto, ON, M5G 1X5, Canada,

Published: September 2015

AI Article Synopsis

  • The study aimed to evaluate a personalized risk stratification and radioactive iodine (RAI) selection protocol (PRSP) to determine when RAI is necessary for patients with low- and intermediate-risk papillary thyroid carcinoma (PTC), based on post-operative tests.
  • Researchers followed 129 patients after total thyroidectomy and analyzed post-surgery stimulated thyroglobulin (Stim-Tg) levels and neck ultrasounds to guide RAI treatment, finding that many patients could safely avoid RAI therapy.
  • Results indicated that 90% of patients in the study did not develop residual or recurrent disease without RAI, suggesting that conventional risk factors for RAI treatment might lead to unnecessary procedures in many cases.

Article Abstract

The purpose of this study was to demonstrate the utility of a personalized risk stratification and radioactive iodine (RAI) selection protocol (PRSP) using post-operative stimulated thyroglobulin (Stim-Tg) and neck ultrasound in low- and intermediate-risk papillary thyroid carcinoma (PTC) patients. Patients with PTC tumors ≥1 cm were prospectively followed after total thyroidectomy and selective therapeutic central compartment neck dissection. Low/intermediate risk was defined as PTC confined to the thyroid or central (level VI) lymph nodes. Stim-Tg and neck ultrasound were performed approximately 3 months after surgery and used to guide RAI selection. Patients with Stim-Tg < 1 µg/L did not receive RAI, while those with Stim-Tg >5 µg/L routinely did. Those with Stim-Tg 1-5 µg/L received RAI on the basis of several clinical risk factors. Patients were followed for >6 years with serial neck ultrasound and basal/stimulated thyroglobulin. Among the 129 patients, 84 (65 %) had undetectable Stim-Tg after initial surgery, 40 (31 %) had Stim-Tg of 1-5 µg/L, and 5 (4 %) had Stim-Tg >5 µg/L. RAI was administered to 8 (20 %) patients with Stim-Tg 1-5 µg/L and 5 (100 %) with Stim-Tg >5 µg/L. Using this approach, RAI therapy was avoided in 17/20 (85 %) patients with tumors >4 cm, in 72/81 (89 %) patients older than 45 years, and in 6/9 (67 %) patients with central lymph node involvement. To date, 116 (90 %) patients in this cohort have not received RAI therapy with no evidence of residual/recurrent disease, whereas among the 13 patients who received RAI, 1 (8 %) had pathologic residual/recurrence disease. Using the proposed PRSP, RAI can be avoided in the majority of low/intermediate-risk PTC patients. Moreover, traditional risk factors considered to favor RAI treatment were not always concordant with the PRSP and may lead to overtreatment.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12020-015-0575-0DOI Listing

Publication Analysis

Top Keywords

neck ultrasound
16
stim-tg µg/l
16
patients
12
stim-tg 1-5
12
1-5 µg/l
12
received rai
12
rai
10
stim-tg
10
post-operative stimulated
8
stimulated thyroglobulin
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!